DMAC DiaMedica Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DMAC

Price (delayed)

$2.63

Market cap

$99.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$95.69M

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.

Highlights
DMAC's debt is down by 15% year-on-year and by 4.8% since the previous quarter
DiaMedica Therapeutics's equity has soared by 60% YoY but it has decreased by 8% from the previous quarter
The quick ratio has grown by 23% YoY but it has contracted by 11% from the previous quarter
The net income has contracted by 41% YoY and by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.diamedica.com
Peers: OMER OMGA

Key stats

What are the main financial stats of DMAC
Market
Shares outstanding
37.96M
Market cap
$99.83M
Enterprise value
$95.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$19.26M
EBITDA
-$19.16M
Free cash flow
-$18.75M
Per share
EPS
-$0.6
Free cash flow per share
-$0.58
Book value per share
$1.35
Revenue per share
$0
TBVPS
$1.66
Balance sheet
Total assets
$54.16M
Total liabilities
$3.1M
Debt
$400,000
Equity
$51.06M
Working capital
$50.89M
Liquidity
Debt to equity
0.01
Current ratio
19.27
Quick ratio
19.12
Net debt/EBITDA
0.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37.7%
Return on equity
-39.9%
Return on invested capital
-42.4%
Return on capital employed
-37.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DMAC stock price

How has the DiaMedica Therapeutics stock price performed over time
Intraday
1.54%
1 week
3.95%
1 month
-3.66%
1 year
62.35%
YTD
-7.39%
QTD
-5.05%

Financial performance

How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.27M
Net income
-$19.3M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 52% YoY and by 10% from the previous quarter
The net income has contracted by 41% YoY and by 8% from the previous quarter

Growth

What is DiaMedica Therapeutics's growth rate over time

Valuation

What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
1.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 15% YoY but it rose by 3.2% QoQ
DiaMedica Therapeutics's equity has soared by 60% YoY but it has decreased by 8% from the previous quarter
The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 3.4 but 9% more than its last 4 quarters average of 1.8

Efficiency

How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on equity has decreased by 6% YoY but it has increased by 3.2% QoQ
The return on assets has declined by 5% year-on-year but it is up by 2.8% since the previous quarter
DiaMedica Therapeutics's return on invested capital has increased by 3.9% QoQ but it has decreased by 3.4% YoY

Dividends

What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMAC.

Financial health

How did DiaMedica Therapeutics financials performed over time
The total assets has soared by 57% year-on-year but it is down by 7% since the previous quarter
DiaMedica Therapeutics's total liabilities has increased by 24% from the previous quarter and by 21% YoY
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has soared by 60% YoY but it has decreased by 8% from the previous quarter
DMAC's debt is down by 15% year-on-year and by 4.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.